Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda

Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm.